Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12624001105538p
Ethics application status
Not yet submitted
Date submitted
28/08/2024
Date registered
13/09/2024
Date last updated
13/09/2024
Date data sharing statement initially provided
13/09/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
Understanding the Abscopal Effect of Low-Dose Localised Radiotherapy in Follicular Lymphoma: The AFL study
Scientific title
Understanding the Abscopal Effect of Involved-Site Radiotherapy in Patients with Follicular Lymphoma Aged 40 years and over: The AFL study
Secondary ID [1] 312830 0
None
Universal Trial Number (UTN)
Trial acronym
The AFL Study
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Follicular Lymphoma 334897 0
Condition category
Condition code
Cancer 331478 331478 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Consented patients with Follicular Lymphoma (either disease recurrence or slow growing/stable lymphoma) in more than one site of disease will receive low dose localised radiotherapy (involved-site radiotherapy or ISRT) to some (not all) of their known lymphoma disease sites at the discretion of the treating radiation oncologist.
Along with standard of care FDG-PET/CT scans prior to radiotherapy (within 60 days), a single 89Zr-durvalumab PET/CT and two (at 1-2 hours and 24 hours post 89Zr- IAB22M2C infusion) 89Zr- IAB22M2C PET/CT scans will be performed – all given over a 5-10 minute infusion and each scan will take 30-45 mins spent on the PET/CT scanner. Patients will be administered 3.0mCi/8ml of89Zr- IAB22M2C during the infusion using a syringe pump. 10 mg of unlabeled durvalumab will be infused over 30 min. After 60 min of observation, the patient will receive 89Zr-durvalumab (60 mBq/70 k up to no more than 74MBq with a concentration of 4 ug/MBq). All PET scans will be acquired according to current departmental guidelines on an integrated PET/CT. This will be reported by a qualified PET physician who will also administer these tracers. The delayed timing of PET image acquisition (4-5 days after tracer administration) is due to the long physical and physiological half-lives of the tracer, and timing.
20ml routine and study blood samples will also be taken at this timepoint. Then, ISRT will be delivered to lesions that are selected and will receive 4 Gy in 2 fractions, delivered on consecutive days. 2 weeks post ISRT, study and routine bloods will be collected along with another two 89Zr- IAB22M2C PET/CT scan’s (again 1-2 hrs and 24hrs post infusion). Lastly, at 6-8 weeks post ISRT, standard of care bloods will be collected along with standard management FDG-PET scans. Following completion of the imaging and pathology phase of the study participants will return to standard of care follow up with their radiation oncologist and/or haematologist approximately 3 months post involvement.
Intervention code [1] 329356 0
Diagnosis / Prognosis
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 339197 0
Composite primary outcome: Local abscopal response per lesion or nodal station on FDG-PET and overall (whole body abscopal response on FDG PET)
Timepoint [1] 339197 0
Baseline (pre-treatment) and follow up FDG-PET imaging 6 weeks after ISRT
Secondary outcome [1] 439055 0
Uptake of tracer in each known lymphoma site
Timepoint [1] 439055 0
At baseline and 2-6 weeks post ISRT, translational bloods will be collected and CD8 and PD-L1 imaging will be assessed.

Eligibility
Key inclusion criteria
1) Eligible to receive palliative ISRT for histologically confirmed low grade (WHO grade1,2 or 3a) follicular lymphoma,
2) Requiring ISRT to local disease for palliation or prevention of local disease progression, or eligible for a “watchful waiting” approach to management
3) >2 lymphoma lesions visualized on FDG-PET scan, with FDG uptake > liver (not including spleen or bone marrow disease)
4) >1 FDG-avid lesion(s) located outside planned ISRT volume, with FDG uptake > liver (not including spleen or bone marrow disease)
5) No systemic therapy (chemo or immunotherapy) delivered in the 2 months before radiation therapy
6) No systemic therapy planned for at least 2 months after ISRT
7) Capable of giving informed consent
8) Life expectancy > 12 months
9) ECOG performance status 0-1 (or 2 if impairment is not related to lymphoma)
10) Available FFPE biopsy specimen confirming diagnosis of FL, suitable for translational studies
11) Age >40
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1) Initial presentation of stage II disease suitable for curative intent RT
2) Any active high grade lymphoma
3) Any prior history of aggressive or transformed lymphoma
4) >2 prior systemic therapy regimens
5) Taking any immunosuppressive medication (e.g. steroids)
6) Active autoimmune disease
7) Neutropaenia (<1.0 x 109)
8) All FDG-avid disease sites are considered to be high priority for early treatment with ISRT and no lesion can safely be left untreated
9) Irradiation of a lesion selected for ISRT would inadvertently irradiate all nominally “untreated” lesions, intended for observation, to > 0.4 Gy
10) Palliative ISRT is required within 7 days for rapid symptom relief
11) Women who are pregnant or who are breastfeeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Bio-availability
Statistical methods / analysis
The primary endpoint is the abscopal regression rate. This is the proportion of patients who after ISRT experience regression of any unirradiated, previously FDG-avid lymphoma lesions, as detected on follow up FDG-PET imaging 6 weeks after ISRT. The abscopal regression rate will be assessed both per lesion/nodal station and overall per patient as follows.
Local abscopal response per lesion or nodal station on FDG-PET; Complete metabolic response (CMR) defined by a Deauville score of 1-3, Partial metabolic response (PMR) analysed by a visually appreciable reduction in FDG uptake, therefore reduction of SUV max, stable metabolic disease (SMD) or progressive metabolic disease (defined by Deauville score of 4 or 5).

Overall (whole body) abscopal response on FDG PET will also be analysed by:
Allocating patients to one of the following overall abscopal response categories based on a consideration of all disease sites in pre and post treatment FDG-PET scans.
a) Complete abscopal response: CMR in all unirradiated lesions and no new lesions
b) Partial abscopal response: at least a PMR in all unirradiated lesions but without a CMR in all unirradiated lesions and no new lesions
b) Mixed abscopal response: CMR or PMR in one or more unirradiated lesions but SMD, or PMD in any other lesion(s). May have one or more new lesions.
c) No abscopal response: No CMR or PMR in any unirradiated lesion

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/01/2025
Actual
Date of last participant enrolment
Anticipated
1/01/2027
Actual
Date of last data collection
Anticipated
1/04/2027
Actual
Sample size
Target
10
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 317253 0
Commercial sector/Industry
Name [1] 317253 0
Varian
Country [1] 317253 0
Australia
Primary sponsor type
Hospital
Name
Peter MacCallum Cancer Centre
Address
Country
Australia
Secondary sponsor category [1] 319547 0
None
Name [1] 319547 0
Address [1] 319547 0
Country [1] 319547 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 315989 0
Peter MacCallum Cancer Centre Human Research Ethics Committee
Ethics committee address [1] 315989 0
Ethics committee country [1] 315989 0
Australia
Date submitted for ethics approval [1] 315989 0
01/11/2024
Approval date [1] 315989 0
Ethics approval number [1] 315989 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 136434 0
Prof Michael MacManus
Address 136434 0
Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne Victoria 3000
Country 136434 0
Australia
Phone 136434 0
+61 03 8559 7761
Fax 136434 0
Email 136434 0
[email protected]
Contact person for public queries
Name 136435 0
Michael MacManus
Address 136435 0
Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne Victoria 3000
Country 136435 0
Australia
Phone 136435 0
+61 03 8559 7761
Fax 136435 0
Email 136435 0
[email protected]
Contact person for scientific queries
Name 136436 0
Michael MacManus
Address 136436 0
Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne Victoria 3000
Country 136436 0
Australia
Phone 136436 0
+61 03 8559 5000
Fax 136436 0
Email 136436 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.